



**November 14, 2024**

**Ref:- GHL/2024-25/EXCH/81**

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrp Code: 543654**

**Symbol: MEDANTA**

**Sub:** Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (*'Listing Regulations'*)

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited (**'GHL/Company'**) at its meeting held today i.e. *Thursday, November 14, 2024*, has *inter alia*, approved:


1) Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2024 (**'Results'**);

The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandio & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Exhibit**, pursuant to Regulation 33 of the Listing Regulations.

2) The recommendation to the shareholders of the Company of formulation of Global Health Limited (GHL) Employees Long Term Share Based Incentive Plan - 2024 ("GHL LTIP 2024 Plan") consisting of Part A- GHL Employees Stock Option Scheme, 2024 and Part B- GHL Employees Stock Purchase Scheme, 2024, to grant the stock options/equity shares to eligible Employees of the Company and/ or its Subsidiary Companies and/ or its Associate Companies, in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SBEB & SE' Regulations, 2021) and subject to regulatory/statutory approvals, as may be necessary. The details as required under Regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed in **Annexure A**;

The Company shall seek the approval of Members through Postal Ballot and the Notice of Postal Ballot, will be sent to all the Members of the Company whose names appear on the Register of Members/List of Beneficial Owners as received from Depositories, as on Friday, November 22, 2024 ('Cut-off date').

3) Allotment of 40,000 Equity Shares of Rs. 2/- each to one (1) eligible employee upon exercise of 8,000 stock options vested under ESOP 2016 Scheme. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from **Rs. 53,70,94,764/- to Rs. 53,71,74,764/-**.





The details as required under Regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and details as required under Regulation 10(c) of the SEBI SBE & SE Regulations, 2021 are enclosed in **Annexure B**; and

4) Accepted the resignation of Mr. Venkatesh Ratnasami (DIN: 03433678), pursuant to letter received from M/s Dunearn Investments (Mauritius) Pte. Ltd., advising the withdrawal of his nomination as a Nominee Director of the Company. Additional details for the same are enclosed in **Annexure C**. Further, pursuant to the resignation of Mr. Venkatesh Ratnasami (DIN: 03433678), the Audit Committee of the Company has been re-constituted.

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.


The meeting of the Board of Directors commenced at 11.00 A.M. and concluded at 01:20 P.M.

Thanking You,

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**



---

**Walker Chandiook & Co LLP**  
21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II,  
Gurugram - 122 002  
Haryana, India  
T +91 124 462 8099  
F +91 124 462 8001

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Global Health Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2024 and the consolidated year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



---

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida, and Pune

---

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

## Walker Chandiook & Co LLP

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013

*Tarun*

**Tarun Gupta**  
Partner  
Membership No. 507892



UDIN: 24507892BKEJAJ6730

**Place:** Gurugram  
**Date:** 14 November 2024

# Walker ChandioK &Co LLP

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

## List of entities included in the Statement

| S. No. | Name  | Relationship with the Holding Company |
|--------|---|---------------------------------------|
| 1      | Medanta Holdings Private Limited  | Wholly owned subsidiary               |
| 2      | Global Health Patliputra Private Limited  | Wholly owned subsidiary               |
| 3      | GHL Pharma & Diagnostic Private Limited<br>(Formerly known as Global Health<br>Pharmaceuticals Private Limited) | Wholly owned subsidiary               |
| 4      | GHL Hospital Limited (incorporated on 11<br>December 2023)  | Subsidiary                            |
| 5      | Global Health Institute of Medical Sciences<br>Foundation (incorporated on 30 March 2024)                       | Wholly owned subsidiary               |



**Global Health Limited**  
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India  
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India  
CIN: L85110DL2004PLC128319  
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org  
Statement of Consolidated Unaudited Financial Results for the quarter and six months ended 30 September 2024

(₹ in millions, unless otherwise stated)

| S. No. | Particulars   | Quarter ended     |                 |                   | Six months ended  |                   | Year ended       |
|--------|---|-------------------|-----------------|-------------------|-------------------|-------------------|------------------|
|        |   | 30 September 2024 | 30 June 2024    | 30 September 2023 | 30 September 2024 | 30 September 2023 | 31 March 2024    |
|        |   | (Unaudited)       | (Unaudited)     | (Unaudited)       | (Unaudited)       | (Unaudited)       | (Audited)        |
|        | <b>Income</b>   |                   |                 |                   |                   |                   |                  |
| I      | Revenue from operations   | 9,565.55          | 8,610.77        | 8,504.46          | 18,176.32         | 16,300.26         | 32,751.11        |
| II     | Other income  | 182.16            | 219.27          | 142.44            | 401.43            | 291.62            | 746.64           |
|        | <b>Total income</b>   | <b>9,747.71</b>   | <b>8,830.04</b> | <b>8,646.90</b>   | <b>18,577.75</b>  | <b>16,591.88</b>  | <b>33,497.75</b> |
|        | <b>Expenses</b>   |                   |                 |                   |                   |                   |                  |
| III    | Cost of materials consumed  | 2,042.75          | 1,876.05        | 1,744.12          | 3,918.80          | 3,389.29          | 6,876.86         |
|        | Purchases of stock-in-trade   | 281.54            | 230.97          | 199.72            | 512.51            | 382.71            | 739.68           |
|        | Changes in inventories of stock-in-trade  | (44.47)           | (18.38)         | (8.05)            | (62.85)           | (22.49)           | (22.94)          |
|        | Employee benefits expense   | 2,142.86          | 2,011.85        | 1,839.32          | 4,154.71          | 3,620.01          | 7,348.58         |
|        | Finance costs   | 159.75            | 179.79          | 200.89            | 339.54            | 380.04            | 739.13           |
|        | Depreciation and amortisation expense   | 494.30            | 466.18          | 429.10            | 960.48            | 832.93            | 1,727.28         |
|        | Impairment losses on financial assets   | 60.92             | 49.03           | 55.82             | 109.95            | 120.23            | 293.13           |
|        | Retainers and consultants fee   | 1,223.29          | 1,184.79        | 1,072.38          | 2,408.08          | 2,072.62          | 4,270.28         |
|        | Other expenses  | 1,575.78          | 1,413.24        | 1,407.56          | 2,989.02          | 2,700.08          | 5,254.76         |
|        | <b>Total expenses</b>   | <b>7,936.72</b>   | <b>7,393.52</b> | <b>6,940.86</b>   | <b>15,330.24</b>  | <b>13,475.42</b>  | <b>27,226.76</b> |
| IV     | <b>Profit before tax</b>  | <b>1,810.99</b>   | <b>1,436.52</b> | <b>1,706.04</b>   | <b>3,247.51</b>   | <b>3,116.46</b>   | <b>6,270.99</b>  |
|        | Tax expenses  |                   |                 |                   |                   |                   |                  |
|        | Current tax   | 486.08            | 364.21          | 478.82            | 850.29            | 898.00            | 1,777.38         |
|        | Tax pertaining to earlier years   | -                 | -               | -                 | -                 | -                 | 12.35            |
|        | Deferred tax charge/(credit)  | 16.73             | 9.67            | (24.39)           | 26.40             | (53.25)           | (299.34)         |
| V      | <b>Profit after tax</b>   | <b>1,308.18</b>   | <b>1,062.64</b> | <b>1,251.61</b>   | <b>2,370.82</b>   | <b>2,271.71</b>   | <b>4,780.60</b>  |
|        | <b>Other comprehensive income</b>   |                   |                 |                   |                   |                   |                  |
|        | (i) Items that will not be reclassified to statement of profit or loss                          | 10.07             | (27.10)         | 11.99             | (17.03)           | (19.44)           | (12.69)          |
|        | (ii) Income tax relating to items that will not be reclassified to statement of profit or loss  | (2.59)            | 6.83            | (2.40)            | 4.24              | 4.95              | 3.31             |
| VI     | <b>Total other comprehensive income</b>   | <b>7.48</b>       | <b>(20.27)</b>  | <b>9.59</b>       | <b>(12.79)</b>    | <b>(14.49)</b>    | <b>(9.38)</b>    |
| VII    | <b>Total comprehensive income</b>   | <b>1,315.66</b>   | <b>1,042.37</b> | <b>1,261.20</b>   | <b>2,358.03</b>   | <b>2,257.22</b>   | <b>4,771.22</b>  |
|        | <b>Profit after tax attributable to:</b>  |                   |                 |                   |                   |                   |                  |
|        | (i) Owners of the Holding Company   | 1,308.44          | 1,062.86        | 1,251.61          | 2,371.30          | 2,271.71          | 4,781.94         |
|        | (ii) Non-controlling interests  | (0.26)            | (0.22)          | -                 | (0.48)            | -                 | (1.34)           |
|        | <b>Other comprehensive income attributable to:</b>  |                   |                 |                   |                   |                   |                  |
|        | (i) Owners of the Holding Company   | 7.48              | (20.27)         | 9.59              | (12.79)           | (14.49)           | (9.38)           |
|        | (ii) Non-controlling interests  | -                 | -               | -                 | -                 | -                 | -                |
|        | <b>Total comprehensive income attributable to:</b>  |                   |                 |                   |                   |                   |                  |
|        | (i) Owners of the Holding Company   | 1,315.92          | 1,042.59        | 1,261.20          | 2,358.51          | 2,257.22          | 4,772.56         |
|        | (ii) Non-controlling interests  | (0.26)            | (0.22)          | -                 | (0.48)            | -                 | (1.34)           |
| VIII   | Paid-up equity share capital (face value of ₹ 2 each)   | 537.09            | 537.01          | 536.81            | 537.09            | 536.81            | 537.01           |
| IX     | Reserves (other equity)   |                   |                 |                   |                   |                   | 28,519.26        |
| X      | Earnings per share (face value of ₹ 2 each)<br>(not annualised for the quarters and six months) |                   |                 |                   |                   |                   |                  |
|        | Basic (₹ per share)   | 4.87              | 3.96            | 4.66              | 8.83              | 8.46              | 17.80            |
|        | Diluted (₹ per share)   | 4.87              | 3.96            | 4.66              | 8.83              | 8.46              | 17.80            |

See accompanying notes to the consolidated unaudited financial results.



(₹ in millions, unless otherwise stated)

| Particulars  | As at                            | As at                      |
|--|----------------------------------|----------------------------|
|  | 30 September 2024<br>(Unaudited) | 31 March 2024<br>(Audited) |
| <b>ASSETS</b>  |                                  |                            |
| <b>Non-current assets</b>  |                                  |                            |
| Property, plant and equipment  | 19,101.32                        | 18,129.25                  |
| Right of use assets  | 5,451.06                         | 4,186.99                   |
| Capital work-in-progress   | 4,528.78                         | 3,862.79                   |
| Intangible assets  | 34.02                            | 42.81                      |
| Intangible assets under development  | 58.45                            | 12.62                      |
| Financial assets   |                                  |                            |
| Investments  | 27.10                            | 0.50                       |
| Other financial assets   | 491.96                           | 271.78                     |
| Deferred tax assets (net)  | 601.38                           | 613.24                     |
| Income-tax assets (net)  | 616.71                           | 660.35                     |
| Other non-current assets   | 182.90                           | 173.12                     |
| <b>Total non-current assets</b>  | <b>31,093.48</b>                 | <b>27,953.45</b>           |
| <b>Current assets</b>  |                                  |                            |
| Inventories  | 757.49                           | 668.50                     |
| Financial assets   |                                  |                            |
| Trade receivables  | 2,830.09                         | 2,153.13                   |
| Cash and cash equivalents  | 2,997.67                         | 4,246.08                   |
| Bank balances other than cash and cash equivalents                                       | 6,830.89                         | 7,506.75                   |
| Other financial assets   | 357.99                           | 344.20                     |
| Other current assets   | 233.20                           | 168.64                     |
| <b>Total current assets</b>  | <b>14,007.33</b>                 | <b>15,087.30</b>           |
| <b>Total assets</b>  | <b>45,100.81</b>                 | <b>43,040.75</b>           |
| <b>EQUITY AND LIABILITIES</b>  |                                  |                            |
| <b>Equity</b>  |                                  |                            |
| Equity share capital   | 537.09                           | 537.01                     |
| Other equity   | 30,877.77                        | 28,519.26                  |
| Non-controlling interests  | 11.68                            | (0.34)                     |
| <b>Total equity</b>  | <b>31,426.54</b>                 | <b>29,055.93</b>           |
| <b>Liabilities</b>   |                                  |                            |
| <b>Non-current liabilities</b>   |                                  |                            |
| Financial liabilities  |                                  |                            |
| Borrowings   | 1,922.05                         | 2,834.66                   |
| Lease liabilities  | 3,473.03                         | 3,465.16                   |
| Other financial liabilities  | 453.82                           | 399.10                     |
| Provisions   | 660.92                           | 577.41                     |
| Deferred tax liabilities (net)   | 251.87                           | 241.58                     |
| Other non-current liabilities  | 384.20                           | 289.58                     |
| <b>Total non-current liabilities</b>   | <b>7,145.89</b>                  | <b>7,807.49</b>            |
| <b>Current liabilities</b>   |                                  |                            |
| Financial liabilities  |                                  |                            |
| Borrowings   | 1,096.71                         | 1,358.71                   |
| Lease liabilities  | 392.95                           | 360.16                     |
| Trade payables   |                                  |                            |
| - Total outstanding dues of micro enterprises and small enterprises                      | 750.48                           | 713.74                     |
| - Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,320.07                         | 1,154.04                   |
| Other financial liabilities  | 1,360.64                         | 1,303.12                   |
| Other current liabilities  | 1,081.54                         | 922.79                     |
| Provisions   | 414.56                           | 364.77                     |
| Current tax liabilities (net)  | 111.43                           | -                          |
| <b>Total current liabilities</b>   | <b>6,528.38</b>                  | <b>6,177.33</b>            |
| <b>Total equity and liabilities</b>  | <b>45,100.81</b>                 | <b>43,040.75</b>           |



(₹ in millions, unless otherwise stated)

| Particulars   | For the period ended<br>30 September 2024 | For the period ended<br>30 September 2023 |
|---|---|---|
|   | (Unaudited)                               | (Unaudited)                               |
| <b>A CASH FLOWS FROM OPERATING ACTIVITIES</b>   |   |   |
| Profit before tax   | 3,247.51                                  | 3,116.46                                  |
| <b>Adjustments for:</b>   |   |   |
| Depreciation and amortisation expense   | 960.48                                    | 832.93                                    |
| Gain on sale of property, plant and equipments (net)  | (6.52)                                    | (7.69)                                    |
| Liabilities written back  | (7.83)                                    | -   |
| Government grants income  | (29.69)                                   | (24.51)                                   |
| Interest income   | (360.54)                                  | (258.35)                                  |
| Unrealised foreign exchange - loss (net)  | 3.88                                      | 0.35                                      |
| Finance costs   | 339.54                                    | 380.05                                    |
| Impairment losses on financial assets   | 109.95                                    | 120.23                                    |
| Employee share based payment expense  | -   | 1.56                                      |
| Provision for contingencies (expense)   | 29.54                                     | 29.54                                     |
| <b>Operating profit before working capital changes</b>  | <b>4,286.32</b>                           | <b>4,190.57</b>                           |
| <b>Movement in working capital</b>  |   |   |
| Inventories   | (88.99)                                   | (129.66)                                  |
| Other assets  | (103.19)                                  | (105.57)                                  |
| Trade receivables   | (764.41)                                  | (744.92)                                  |
| Other liabilities   | 60.86                                     | 60.38                                     |
| Trade payables  | 210.61                                    | 343.65                                    |
| Provisions  | 86.73                                     | 31.86                                     |
| <b>Cash flows from operating activities</b>   | <b>3,687.93</b>                           | <b>3,646.31</b>                           |
| Income-tax paid (net)   | (695.23)                                  | (820.34)                                  |
| <b>Net cash flows from operating activities (A)</b>   | <b>2,992.70</b>                           | <b>2,825.97</b>                           |
| <b>B CASH FLOWS FROM INVESTING ACTIVITIES</b>   |   |   |
| Purchase of property, plant and equipments, capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities) | (2,643.54)                                | (1,056.64)                                |
| Payment for acquisition of leasehold land (refer note 7)  | (1,251.11)                                | -   |
| Proceeds from disposal of property, plant and equipments  | 14.17                                     | 9.98                                      |
| Movement in other bank balances (net)   | 644.74                                    | (1,095.87)                                |
| Movement in bank deposits having maturity period more than 12 months (net)  | (216.07)                                  | (369.92)                                  |
| Interest received   | 389.27                                    | 257.34                                    |
| Investment in equity shares   | (26.60)                                   | -   |
| <b>Net cash used in investing activities (B)</b>  | <b>(3,089.14)</b>                         | <b>(2,255.11)</b>                         |
| <b>C CASH FLOWS FROM FINANCING ACTIVITIES</b>   |   |   |
| Proceeds from issue of equity share capital (net of share issue expenses)   | 0.08                                      | 0.42                                      |
| Proceeds from issue of equity share capital to non-controlling interest   | 12.50                                     | -   |
| Proceeds from non-current borrowings  | 341.65                                    | -   |
| Repayment of borrowings   | (1,139.51)                                | (4,281.85)                                |
| Interest paid on borrowings   | (143.15)                                  | (200.55)                                  |
| Payment of interest on lease payments   | (208.49)                                  | (144.09)                                  |
| Principal elements of lease liabilities   | (15.05)                                   | (77.63)                                   |
| <b>Net cash used in financing activities (C)</b>  | <b>(1,151.97)</b>                         | <b>(4,703.70)</b>                         |
| Increase in cash and cash equivalents (A+B+C)   | (1,248.41)                                | (4,132.84)                                |
| Cash and cash equivalents at the beginning of the year  | 4,246.08                                  | 7,672.44                                  |
| <b>Cash and cash equivalents at the end of the period</b>   | <b>2,997.67</b>                           | <b>3,539.60</b>                           |
| <b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>  |   |   |
| Balances with banks in current accounts   | 1,279.34                                  | 1,452.01                                  |
| Cheques on hand   | 0.08                                      | 5.93                                      |
| Cash on hand  | 28.23                                     | 24.22                                     |
| Bank deposits with original maturity less than three months   | 1,690.02                                  | 2,057.44                                  |
|   | <b>2,997.67</b>                           | <b>3,539.60</b>                           |





**Global Health Limited**

**Notes to the consolidated unaudited financial results (cont'd):**

- 3 The above consolidated financial results of Global Health Limited (the Holding Company) and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group') for the quarter and six months ended 30 September 2024 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14 November 2024 and a limited review of the same has been carried out by the statutory auditors.
- 4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 5 The chief operating decision maker (CODM) examines the Group's performance from a service perspective and has identified the Healthcare services as single business segment.
- 6 The Board of Directors of the Holding Company at their meeting held on 21 March 2024 had approved the Scheme of Amalgamation between Medanta Holdings Private Limited, wholly owned subsidiary, (Transferor Company) and the Holding Company (Transferee Company) and their respective members and creditors under section 230 to 232 of the Companies Act, 2013. The Holding Company has filed the application with National Company Law Tribunal, New Delhi (NCLT) on 06 May 2024. Pursuant to the NCLT order dated 12 June 2024, meeting of the unsecured creditors of the Holding Company has been held on 03 August 2024 where the Scheme has been approved and accordingly, Holding Company has filed the second motion petition with NCLT in current period. The matter is listed for hearing in NCLT on 20 November 2024.
- 7 During the period ended 30 September 2024, the Holding Company has acquired land parcel, on lease basis, situated at Mauje-Oshiwara, Jogeshwari, Mumbai, offered by Mumbai Housing and Area Development Authority (MHADA) under online e-tenders.
- 8 Subsequent to period ended 30 September 2024, the Holding Company has executed definitive agreement with Dr. Narayan Dutt Shrimali Foundation International Charitable Trust Society (Society) to operate and manage ~750 bedded hospital in Pitampura, New Delhi.
- 9 The Board of Directors of the Holding Company at its meeting held on 14 November 2024, recommended to the shareholders for approval of Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024 ("GHL Plan 2024") for eligible employees of the Holding Company and its subsidiaries and associates. Under the GHL Plan 2024, which will be implemented through a Trust, the maximum number of shares that may be allotted shall not exceed 1,750,000 equity shares of ₹ 2 each through primary issuance and 5,370,147 equity shares (i.e. 2% of paid up capital of the Holding Company as on 31 March 2024), through secondary acquisition.
- 10 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

**For and on behalf of the Board of Directors of Global Health Limited**

Place : Gurugram

Date : 14 November 2024



*Dr. Naresh Trehan*  
Dr. Naresh Trehan  
Chairman and Managing Director



*la*

---

Walker ChandioK & Co LLP

21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II,  
Gurugram - 122 002  
Haryana, India

T +91 124 462 8099

F +91 124 462 8001

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Global Health Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') for the quarter ended 30 September 2024 and the year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



---

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida, and Pune

---

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

## Walker Chandiook & Co LLP

### Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013



**Tarun Gupta**  
Partner  
Membership No. 507892



**UDIN:** 24507892BKEJAI1820

**Place:** Gurugram  
**Date:** 14 November 2024

Global Health Limited

Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India

CIN:L85110D12004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 September 2024

(₹ in millions, unless otherwise stated)

| S No. | Particulars   | Quarter ended     |                 |                   | Six months period ended |                   | Year ended       |
|-------|---|-------------------|-----------------|-------------------|-------------------------|-------------------|------------------|
|       |   | 30 September 2024 | 30 June 2024    | 30 September 2023 | 30 September 2024       | 30 September 2023 | 31 March 2024    |
|       |   | (Unaudited)       | (Unaudited)     | (Unaudited)       | (Unaudited)             | (Unaudited)       | (Audited)        |
|       | <b>Income</b>   |                   |                 |                   |                         |                   |                  |
| I     | Revenue from operations   | 6,646.06          | 6,114.49        | 5,860.16          | 12,760.55               | 11,365.23         | 22,800.08        |
| II    | Other income  | 235.79            | 266.98          | 203.65            | 502.77                  | 476.49            | 1,028.68         |
|       | <b>Total income</b>   | <b>6,881.85</b>   | <b>6,381.47</b> | <b>6,063.81</b>   | <b>13,263.32</b>        | <b>11,841.72</b>  | <b>23,828.76</b> |
|       | <b>Expenses</b>   |                   |                 |                   |                         |                   |                  |
| III   | Cost of materials consumed  | 1,321.11          | 1,405.61        | 1,265.70          | 2,926.72                | 2,469.05          | 5,061.46         |
|       | Purchases of stock-in-trade   | 117.83            | 116.91          | 111.26            | 234.74                  | 222.76            | 423.39           |
|       | Changes in inventories of stock-in-trade  | 2.15              | (5.24)          | 0.37              | (3.09)                  | (9.83)            | (6.25)           |
|       | Employee benefits expense   | 1,680.98          | 1,575.01        | 1,486.92          | 3,255.99                | 2,945.23          | 5,910.62         |
|       | Finance costs   | 53.68             | 59.52           | 61.06             | 113.20                  | 124.87            | 244.57           |
|       | Depreciation and amortisation expense   | 249.09            | 233.03          | 215.42            | 482.12                  | 419.70            | 870.90           |
|       | Impairment losses on financial assets   | 56.12             | 36.03           | 55.31             | 92.15                   | 118.72            | 277.32           |
|       | Retainers and consultants fee   | 658.30            | 653.57          | 579.13            | 1,311.87                | 1,126.42          | 2,332.12         |
|       | Other expenses  | 1,106.50          | 1,009.60        | 1,019.72          | 2,116.10                | 1,998.50          | 3,827.92         |
|       | <b>Total expenses</b>   | <b>5,445.76</b>   | <b>5,084.04</b> | <b>4,794.89</b>   | <b>10,529.80</b>        | <b>9,415.42</b>   | <b>18,942.05</b> |
| IV    | <b>Profit before tax</b>  | <b>1,436.09</b>   | <b>1,297.43</b> | <b>1,268.92</b>   | <b>2,733.52</b>         | <b>2,426.30</b>   | <b>4,886.71</b>  |
| V     | Tax expenses  |                   |                 |                   |                         |                   |                  |
|       | Current tax   | 413.82            | 321.47          | 350.45            | 735.29                  | 695.95            | 1,383.40         |
|       | Tax pertaining to earlier years   | -                 | -               | -                 | -                       | -                 | 12.35            |
|       | Deferred tax (credit)/charge  | (22.39)           | 13.12           | (32.48)           | (9.27)                  | (82.71)           | (117.95)         |
| VI    | <b>Profit after tax</b>   | <b>1,044.66</b>   | <b>962.84</b>   | <b>950.95</b>     | <b>2,007.50</b>         | <b>1,813.06</b>   | <b>3,608.91</b>  |
| VII   | <b>Other comprehensive income</b>   |                   |                 |                   |                         |                   |                  |
|       | A (i) Items that will not be reclassified to statement of profit or loss                        | 9.51              | (25.38)         | 8.84              | (15.87)                 | (19.74)           | (14.91)          |
|       | (ii) Income-tax relating to items that will not be reclassified to statement of profit or loss  | (2.40)            | 6.39            | (2.23)            | 3.99                    | 4.97              | 3.75             |
|       | <b>Total other comprehensive income</b>   | <b>7.11</b>       | <b>(18.99)</b>  | <b>6.61</b>       | <b>(11.88)</b>          | <b>(14.77)</b>    | <b>(11.16)</b>   |
| VIII  | <b>Total comprehensive income</b>   | <b>1,051.77</b>   | <b>943.85</b>   | <b>957.56</b>     | <b>1,995.62</b>         | <b>1,798.29</b>   | <b>3,597.75</b>  |
| IX    | Paid-up equity share capital (face value of ₹ 2 each)   | 537.09            | 537.01          | 536.81            | 537.09                  | 536.81            | 537.01           |
| X     | Reserves (other equity)   |                   |                 |                   |                         |                   | 27,950.97        |
| XI    | Earnings per share (face value of ₹ 2 each)<br>(not annualised for the quarters and six months) |                   |                 |                   |                         |                   |                  |
|       | Basic (₹ per share)   | 3.89              | 3.58            | 3.54              | 7.47                    | 6.75              | 13.44            |
|       | Diluted (₹ per share)   | 3.89              | 3.58            | 3.54              | 7.47                    | 6.75              | 13.44            |

See accompanying notes to the standalone unaudited financial results



(This space has been intentionally left blank)



(₹ in millions, unless otherwise stated)

| Particulars  | As at             |                  |
|--|-------------------|------------------|
|  | 30 September 2024 | 31 March 2024    |
|  | (Unaudited)       | (Audited)        |
| <b>ASSETS</b>  |                   |                  |
| Property, plant and equipment  | 6,327.14          | 5,639.07         |
| Right of use assets  | 3,984.22          | 2,757.17         |
| Capital work-in-progress   | 2,590.62          | 1,833.07         |
| Intangible assets  | 13.33             | 15.84            |
| Intangible assets under development  | 45.94             | 7.82             |
| Financial assets   |                   |                  |
| Investments  | 7,913.48          | 7,900.98         |
| Loans  | 2,839.61          | 2,908.43         |
| Other financial assets   | 420.79            | 177.54           |
| Deferred tax assets (net)  | 392.02            | 378.77           |
| Income-tax assets (net)  | 482.72            | 595.46           |
| Other non-current assets   | 172.14            | 114.10           |
| <b>Total non-current assets</b>  | <b>25,182.01</b>  | <b>22,328.25</b> |
| <b>Current assets</b>  |                   |                  |
| Inventories  | 446.74            | 442.66           |
| Financial assets   |                   |                  |
| Trade receivables  | 2,497.18          | 1,918.68         |
| Cash and cash equivalents  | 1,557.18          | 2,186.67         |
| Bank balances other than cash and cash equivalents                                     | 6,735.26          | 7,405.43         |
| Loans  | 616.85            | 568.74           |
| Other financial assets   | 266.47            | 283.26           |
| Other current assets   | 158.34            | 100.08           |
| <b>Total current assets</b>  | <b>12,278.02</b>  | <b>12,905.52</b> |
| <b>Total assets</b>  | <b>37,460.03</b>  | <b>35,233.77</b> |
| <b>EQUITY AND LIABILITIES</b>  |                   |                  |
| <b>Equity</b>  |                   |                  |
| Equity share capital   | 537.09            | 537.01           |
| Other equity   | 29,946.59         | 27,950.97        |
| <b>Total equity</b>  | <b>30,483.68</b>  | <b>28,487.98</b> |
| <b>Liabilities</b>   |                   |                  |
| <b>Non-current liabilities</b>   |                   |                  |
| Financial liabilities  |                   |                  |
| Lease liabilities  | 1,746.60          | 1,768.24         |
| Provisions   | 576.50            | 511.83           |
| Other non-current liabilities  | 363.88            | 269.78           |
| <b>Total non-current liabilities</b>   | <b>2,686.98</b>   | <b>2,549.85</b>  |
| <b>Current liabilities</b>   |                   |                  |
| Financial liabilities  |                   |                  |
| Borrowings   | 226.30            | 591.81           |
| Lease liabilities  | 257.26            | 242.32           |
| Trade payables   |                   |                  |
| Total outstanding dues of micro enterprises and small enterprises                      | 525.29            | 548.89           |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 895.55            | 829.09           |
| Other financial liabilities  | 1,146.63          | 1,042.60         |
| Other current liabilities  | 776.94            | 637.79           |
| Provisions   | 349.97            | 303.44           |
| Current tax liabilities (net)  | 111.43            | -                |
| <b>Total current liabilities</b>   | <b>4,289.37</b>   | <b>4,195.94</b>  |
| <b>Total equity and liabilities</b>  | <b>37,460.03</b>  | <b>35,233.77</b> |



(₹ in millions, unless otherwise stated)

| Particulars   | For the year ended<br>30 September 2024 | For the year ended<br>30 September 2023 |
|---|---|---|
|   | (Unaudited)                             | (Unaudited)                             |
| <b>A CASH FLOWS FROM OPERATING ACTIVITIES</b>   |   |   |
| Profit before tax   | 2,733.52                                | 2,426.30                                |
| <b>Adjustments for:</b>   |   |   |
| Depreciation and amortisation expense   | 482.12                                  | 419.70                                  |
| Gain on sale of property, plant and equipments (net)  | (7.09)                                  | (7.68)                                  |
| Liabilities written back  | (7.82)                                  |   |
| Government grants income  | (28.16)                                 | (23.60)                                 |
| Interest income   | (465.00)                                | (385.08)                                |
| Unrealised foreign exchange loss/(gain) (net)   | 4.65                                    | (3.95)                                  |
| Finance costs   | 113.20                                  | 124.87                                  |
| Impairment losses on financial assets   | 92.15                                   | 118.72                                  |
| Employee share based payment expense  |   | 1.56                                    |
| Provision for contingencies (expense)   | 29.54                                   | 29.54                                   |
| <b>Operating profit before working capital changes</b>  | <b>2,947.11</b>                         | <b>2,700.38</b>                         |
| <b>Movement in working capital</b>  |   |   |
| Inventories   | (4.08)                                  | (88.69)                                 |
| Other assets  | (66.01)                                 | (117.87)                                |
| Trade receivables   | (647.08)                                | (593.97)                                |
| Other liabilities   | 15.87                                   | (61.92)                                 |
| Trade payables  | 50.65                                   | 23.24                                   |
| Provisions  | 65.29                                   | (10.77)                                 |
| <b>Cash flows from operating activities</b>   | <b>2,362.25</b>                         | <b>2,075.10</b>                         |
| Income tax paid (net)   | (511.11)                                | (646.69)                                |
| <b>Net cash flows from operating activities (A)</b>   | <b>1,851.14</b>                         | <b>1,428.41</b>                         |
| <b>B CASH FLOWS FROM INVESTING ACTIVITIES</b>   |   |   |
| Purchase of property, plant and equipments, capital work in progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities) | (1,690.36)                              | (575.24)                                |
| Payment for acquisition of leasehold land (refer note 7)  | (1,251.11)                              |   |
| Proceeds from disposal of property, plant and equipments  | 12.67                                   | 10.03                                   |
| Movement in other bank balances (net)   | 643.40                                  | (1,109.18)                              |
| Movement in bank deposits having maturity period more than 12 months (net)  | (240.83)                                | (383.39)                                |
| Interest received   | 499.79                                  | 384.18                                  |
| Investment in subsidiary companies  | (12.50)                                 | (250.00)                                |
| Loan to subsidiaries  | (250.00)                                | (3,750.00)                              |
| Loans repayment from subsidiaries   | 270.72                                  | 168.08                                  |
| <b>Net cash used in investing activities (B)</b>  | <b>(2,027.22)</b>                       | <b>(5,505.52)</b>                       |
| <b>C CASH FLOWS FROM FINANCING ACTIVITIES</b>   |   |   |
| Proceeds from issue of equity share capital (net of share issue expenses)   | 0.08                                    | 0.42                                    |
| Repayment of borrowings   | (333.33)                                | (333.33)                                |
| Interest paid on borrowings   | (14.94)                                 | (29.94)                                 |
| Payment of interest on lease payments   | (98.53)                                 | (89.77)                                 |
| Principal elements of lease liabilities   | (6.69)                                  | (66.13)                                 |
| <b>Net cash used in financing activities (C)</b>  | <b>(453.41)</b>                         | <b>(518.75)</b>                         |
| Net decrease in cash and cash equivalents (A+B+C)   | (69.49)                                 | (1,595.86)                              |
| Cash and cash equivalents at the beginning of the year  | 2,186.67                                | 6,427.81                                |
| <b>Cash and cash equivalents at the end of the period</b>   | <b>1,557.18</b>                         | <b>1,831.95</b>                         |
| <b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>  |   |   |
| Balances with banks in current accounts   | 635.33                                  | 856.66                                  |
| Cheques on hand   | 0.04                                    | 5.93                                    |
| Cash on hand  | 14.82                                   | 14.68                                   |
| Bank deposits with original maturity less than three months   | 906.99                                  | 954.68                                  |
|   | <b>1,557.18</b>                         | <b>1,831.95</b>                         |



## Global Health Limited

### Notes to the standalone unaudited financial results (cont'd):

3. The above standalone financial results for the quarter and six months ended on 30 September 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14 November 2024 and a limited review of the same has been carried out by the statutory auditors.
4. These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
5. The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment.
6. The Board of Directors of the Company at their meeting held on 21 March 2024 had approved the Scheme of Amalgamation between Medanta Holdings Private Limited, wholly owned subsidiary, (Transferor Company) and the Company (Transferee Company) and their respective members and creditors under section 230 to 232 of the Companies Act, 2013. The Company has filed the application with National Company Law Tribunal, New Delhi (NCLT) on 06 May 2024. Pursuant to the NCLT order dated 12 June 2024, meeting of the unsecured creditors of the Company has been held on 03 August 2024 where the Scheme has been approved and accordingly, Company has filed the second motion petition with NCLT in current period. The matter is listed for hearing in NCLT on 20 November 2024.
7. During the period ended 30 September 2024, the Company has acquired land parcel, on lease basis, situated at Manje Oshwara, Jogeshwan, Mumbai, offered by Mumbai Housing and Area Development Authority (MHADA) under online e tenders.
8. Subsequent to period ended 30 September 2024, the Company has executed definitive agreement with Dr. Narayan Dutt Shrinani Foundation International Charitable Trust Society (Society) to operate and manage 750 bedded hospital in Pitampura, New Delhi.
9. The Board of Directors of the Company at its meeting held on 14 November 2024, recommended to the shareholders for approval of Global Health Limited Employees Long Term Share Based Incentive Plan - 2024 ("GHL Plan 2024") for eligible employees of the Company and its subsidiaries and associates. Under the GHL Plan 2024, which will be implemented through a Trust, the maximum number of shares that may be allotted shall not exceed 1,750,000 equity shares of ₹ 2 each through primary issuance and 5,370,147 equity shares (i.e. 2% of paid up capital of the Company as on 31 March 2024), through secondary acquisition.
10. Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited



*Naresh Trehan*  
Dr. Naresh Trehan  
Chairman and Managing Director

Place : Gurugram

Date : 14 November 2024



*60*

**Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**GLOBAL HEALTH LIMITED (GHL) EMPLOYEES LONG TERM SHARE BASED INCENTIVE PLAN 2024 (GHL LTIP 2024 Plan) CONSISTING OF:**

**PART A – GHL Employees Stock Option Scheme, 2024 (ESOS 2024)**

**PART B – GHL Employees Stock Purchase Scheme, 2024 (ESPS 2024)**

| S. No. | Particulars   | Description  |
|--------|---|--|
| 1.     | <b>brief details of options granted</b>   | <p>The maximum number of Shares that may be allotted under the GHL LTIP 2024 Schemes shall not exceed 17,50,000 Equity Shares for Primary Allotment and 53,70,147 Equity Shares (i.e. 2% of the paid-up capital of the Company as on March 31, 2024 for Secondary Acquisition. The Nomination &amp; Remuneration Committee (NRC) reserves the right to increase or reduce such number of Shares as it deems fit, subject to Applicable Laws and necessary approvals.</p> <p>The GHL LTIP 2024 Plan will be implemented through a trust set up in a manner as permissible under the SEBI SBEB &amp; SE Regulations, 2021 and subject to applicable compliances, as may be decided by the Board.</p> |
| 2.     | <b>whether the scheme is in terms of SEBI (SBEB) Regulations, 2021, (if applicable)</b> | Yes, the GHL LTIP 2024 Plan is in terms SEBI SBEB & SE Regulations, 2021.  |
| 3.     | <b>Total number of shares covered by these options</b>                                  | <p>The maximum number of Shares that may be allotted under the GHL LTIP 2024 Plan shall not exceed 17,50,000 Equity Shares for Primary Allotment and 53,70,147 Equity Shares (i.e. 2% of the paid-up capital of the Company as on March 31, 2024 for Secondary Acquisition. The NRC reserves the right to increase or reduce such number of Shares as it deems fit, subject to Applicable Laws and necessary approvals.</p> <p><i>Note: Each Option will result into allotment of One (1) Equity Share of Rs. 2/- each.</i></p>  |
| 4.     | <b>pricing formula</b>  | The Exercise Price shall be decided by the Nomination & Remuneration Committee, as on date of Grant, which in any case shall not be less than the face value of Shares of the Company i.e. Rs. 2/- per share and shall be in compliance with the accounting policies as specified in the SEBI SBEB & SE Regulations, 2021.   |



|     |  |  |
|-----|--|--|
| 5.  | options vested   | Not applicable at this stage   |
| 6.  | time within which option may be exercised                            | The Vested Options shall be exercised on the payment of Exercise Price, according to the terms and conditions as determined and set forth under the ESOS 2024 Scheme, within a maximum period of 3 years from the date of vesting of last installment of Options under ESOS 2024 Scheme.<br>In case of ESOS 2024 Scheme, each Offer must be exercised at such time or times and during such period as is determined by the NRC and set forth in the Offer Letter.  |
| 7.  | options exercised  | Not applicable at this stage   |
| 8.  | money realized by exercise of options                                |  |
| 9.  | the total number of shares arising as a result of exercise of option |  |
| 10. | options lapsed   |  |
| 11. | variation of terms of options  |  |
| 12. | brief details of significant terms                                   | <p><b>The Board recommended to shareholders for cancellation of erstwhile GHIL ESOP 2021 Scheme, subject to approval of GHIL LTIP 2024 Plan by Shareholders. The Erstwhile GHIL ESOP 2021 Scheme will stand cancelled immediately, on the approval of GHIL LTIP 2024 Plan.</b></p> <p><b><u>GHIL LTIP 2024 Plan consists of the following:</u></b></p> <p><b>Part A - ESOS 2024; and</b><br/><b>Part B - ESOS 2024</b></p> <p><b><u>Part A – ESOS 2024:</u></b><br/><b>Eligibility:</b> The Scheme contemplates grant of options to the eligible employees of the Company and/ or its Subsidiary Companies and/ or its Associate Companies. NRC of the Company at its sole discretion shall determine the eligibility criteria based on service, designation, performance, loyalty etc.</p> <p><b>Vesting:</b> Options granted under ESOS 2024 shall Vest not earlier than 1 year or such other period as may be provided in the Companies Act and SEBI SBEB Regulations and not later than maximum Vesting Period of 5 years from the date of Grant based on performance rating—service, rank or designation or such other parameters, conditions</p> |

decided by the NRC from time to time. The specific vesting schedule and vesting Conditions subject to which vesting would take place shall be outlined in the Grant Letter.

**Exercise:** The Exercise Price shall be decided by the Nomination & Remuneration Committee, as on date of Grant, which in any case shall not be less than the face value of Shares of the Company i.e. Rs. 2/- per share and shall be in compliance with the accounting policies as specified in the SEBI SBEB & SE Regulations, 2021.

The vested options shall be exercisable on payment of exercise price, according to the terms and conditions, as determined and set forth under the ESOS 2024 within a maximum period of 3 years from the date of vesting of last installment of Options under ESOS 2024.

*Note: Each Option will result into allotment of One (1) Equity Share of Rs. 2/- each.*

### **Part B – ESPS 2024**

**Eligibility:** The Scheme contemplates to offer Shares of the Company to the eligible employees of the Company and/ or its Subsidiary Companies and/ or its Associate Companies. NRC of the Company at its sole discretion shall determine the eligibility criteria based on service, designation, performance, loyalty etc.

**Exercise:** Each offer must be exercised at such time or times and during such period as is determined by the Committee and set forth in the Offer Letter (“Offer Period”). The right to exercise the Shares is available to the eligible employee subject to the terms and conditions of ESPS 2024 and Offer Letter and executing such documents as required by the Committee.

The Exercise Price shall be such as shall be decided by the Committee as on date of Offer which in any case shall not be less than the face value of Shares of the Company and shall be in compliance with the accounting policies as specified in the SEBI SBEB


|     |   |   |
|-----|---|---|
|     |   | <p>Regulations. The specific Exercise Price shall be intimated to the eligible employee in the Offer</p> <p><b>Lock-in:</b> Shares transferred by the trust to the eligible employees shall be subject to a minimum Share Lock-in Period of 1 year and a maximum Share Lock-in Period of 5 years from the date of transfer thereof. The maximum Share Lock-in Period shall be subject to the discretion of the Committee. The employees shall not be allowed to transfer, sell, hypothecate, etc. the shares during the lock-in period.</p> |
| 13. | <b>subsequent changes or cancellation or exercise of such options</b>                       | Not applicable at this stage  |
| 14. | <b>diluted earnings per share pursuant to issue of equity shares on exercise of options</b> | Not applicable at this stage  |



| S. No. | Particulars   | Details  |
|--------|---|--|
| 1.     | Company Name and address of Registered Office   | Global Health Limited<br>Reg. Office Address: Medanta - Mediclinic,<br>E-18, Defence Colony, New Delhi - 110024                        |
| 2.     | Name of the recognized Stock Exchanges on which the company's shares are listed   | BSE; and<br>NSE  |
| 3.     | Filing date of the statement referred in regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange | BSE – 17 <sup>th</sup> February, 2023<br>NSE - 21 <sup>st</sup> February, 2023   |
| 4.     | Filing Number, if any   | BSE Case No. – 168940<br>NSE Case No. – 34323  |
| 5.     | Title of the Scheme pursuant to which shares are issued, if any   | Global Health Limited - Employees Stock Option Scheme 2016<br>(‘ESOP 2016 Scheme’)   |
| 6.     | Kind of security to be listed   | Equity Shares  |
| 7.     | Par value of the shares   | Rs. 2/- each   |
| 8.     | Date of <del>issue of shares</del> / allotment of shares  | <b>November 14, 2024</b>   |
| 9.     | Number of shares <del>issued</del> / allotted   | 40,000 Equity Shares   |
| 10.    | Share Certificate No., if applicable  | NA   |
| 11.    | Distinctive number of the share, if applicable  | 26,85,47,383-26,85,87,382  |
| 12.    | ISIN Number of the shares, if issued in Demat   | INE474Q01031   |
| 13.    | Exercise price per share  | Rs. 2/- each   |
| 14.    | Premium per share   | NA   |
| 15.    | Total issued shares after this <del>issue</del> / allotment   | 26,85,87,382 Equity Shares   |
| 16.    | Total issued share capital after this <del>issue</del> / allotment (in Rs.)   | Rs. 53,71,74,764/-   |
| 17.    | Details of any lock-in on the shares  | NA   |
| 18.    | Date of expiry of lock-in   | NA   |
| 19.    | Whether shares are identical in all respects to existing shares? If not, when will they become identical?   | All Equity Shares allotted pursuant to exercise of stock options shall rank pari-passu with the existing Equity Shares of the Company. |
| 20.    | Details of listing fees, if payable   | NA   |

Annexure C

| S. No. | Particulars  | Information of event  |
|--------|--|---|
| 1.     | Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise;</del>                 | Resignation   |
| 2.     | Date of <del>appointment/re-appointment/cessation</del> (as applicable) & <del>term of appointment/re-appointment;</del> | November 14, 2024   |
| 3.     | Brief profile (in case of appointment);  | NA  |
| 4.     | Disclosure of relationships between directors (in case of appointment of a director)                                     | NA  |
| 5.     | Letter of Resignation along with detailed reasons for resignation  | Withdrawal of Mr. Venkatesh Ratnasami nomination by M/s Dunearn Investments (Mauritius) Pte. Ltd., as a Nominee Director of the Company. Resignation Letter is attached as <b>Exhibit A</b> . |



ANNEXURE A

Exhibit A

Date: 14 November 2024

To,  
The Board of Directors,  
Global Health Limited (“Company”)  
Medanta-Mediclinic, E-18,  
Defence Colony, New Delhi - 110024, India.

**Sub: Resignation as Director**

Dear Sir,

Pursuant to the letter dated 14 November 2024, issued by Dunearn Investments (Mauritius) Pte. Ltd., and provisions of Section 168(1) of The Companies Act, 2013 read with Rule 16 of the Companies (Appointment and Qualification of Directors) Rules, 2014, I, Ratnasami Venkatesh presently appointed as a nominee non-executive director on behalf of Dunearn Investments (Mauritius) Pte. Ltd. of the Company, hereby tender my resignation as the director of the Company with effect from the date of this resignation letter.

Kindly confirm my resignation and arrange to file the necessary e-forms with the office of the Registrar of Companies / Ministry of Corporate Affairs to that effect.

I would like to thank the other directors on board of directors of the Company for the support provided during my tenure.

Thanking You.

Yours sincerely,



Ratnasami Venkatesh

DIN: 03433678